Search

Your search keyword '"Meyerhardt, J"' showing total 170 results

Search Constraints

Start Over You searched for: Author "Meyerhardt, J" Remove constraint Author: "Meyerhardt, J"
170 results on '"Meyerhardt, J"'

Search Results

2. Alliance A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer – Evaluating Radiation, Ablation and Surgery (ERASur)

3. A Single-Institution Experience of Acute Neuropathic Lumbosacral Pain in Patients Treated with Short Course Hypofractionated Radiotherapy in Locally Advanced Rectal Cancer

4. Histopathology images predict multi-omics aberrations and prognoses in colorectal cancer patients

5. Bayesian risk prediction model for colorectal cancer mortality through integration of clinicopathologic and genomic data

6. Inverse relationship between Fusobacterium nucleatum amount and tumor CD274 (PD-L1) expression in colorectal carcinoma

7. Radiation Therapy (RT) Quality Assurance (QA) Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas (PDAC)

8. 317MO Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: An ACCENT/IDEA pooled analysis of 12 trials

9. LBA26 SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)

10. 1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses

11. SO-38 Clinical efficacy and single-cell analysis of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients

12. Spatial organization and prognostic significance of NK and NKT-like cells via multimarker analysis of the colorectal cancer microenvironment

14. Association of Fusobacterium nucleatum with specific T-cell subsets in the colorectal carcinoma microenvironment

16. Tumor long interspersed nucleotide element-1 (LINE-1) hypomethylation in relation to age of colorectal cancer diagnosis and prognosis

17. The prognostic role of macrophage polarization in the colorectal cancer microenvironment

18. Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma

19. Prognostic significance of myeloid immune cells and their spatial distribution in the colorectal cancer microenvironment

21. SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients

24. Prognostic significance of immune cell populations identified by machine learning in colorectal cancer using routine hematoxylin and eosin–stained sections

25. An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer

26. Metabolic profiling of formalin-fixed paraffin-embedded tissues discriminates normal colon from colorectal cancer

27. Smoking status at diagnosis and colorectal cancer prognosis according to tumor lymphocytic reaction

28. Association of autophagy status with amount of Fusobacterium nucleatum in colorectal cancer

29. Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer

32. Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)

33. Levels of endogenous anti-beta-glucan IgG antibodies (ABA) predict clinical outcomes for imprime PGG: Evidence from phase 3 PRIMUS study in patients (pts) with metastatic colorectal cancer (mCRC)

35. The Idea (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: a Prospective Pooled Non-Inferiority Analysis of > 11,500 Patients from 6 Phase III Trials of Adjuvant Therapy Duration with Folfox (Folfox4 or Mfolfox6) or Xelox (3 Vs. 6 Months) for Stage III Colon Cancer

36. Response

41. Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803

49. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

50. Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) in combination with gemcitabine (GEM) and oxaliplatin (OX)

Catalog

Books, media, physical & digital resources